Login / Signup

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.

Dafna D GladmanLaura C CoatesJoseph WuLara FallonElizabeth D BacciJoseph C CappelleriAndrew G BushmakinPhilip S Helliwell
Published in: Arthritis research & therapy (2022)
ClinicalTrials.gov , NCT01877668. Registered June 12, 2013. ClinicalTrials.gov , NCT01882439. Registered June 18, 2013.
Keyphrases
  • patient reported outcomes
  • rheumatoid arthritis
  • ulcerative colitis
  • juvenile idiopathic arthritis
  • double blind
  • clinical trial
  • randomized controlled trial
  • phase iii
  • newly diagnosed